Organotrifluoroborate Enhances Tumour Targeting of Fibroblast Activation Protein Inhibitors for Targeted Radionuclide Therapy

被引：0
|
作者：
Liu, Yu [1 ]
Tang, Haocheng [1 ]
Song, Tianchi [1 ]
Liu, Zhibo [1 ]
机构：
[1] Peking Univ, Beijing, Peoples R China
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P950
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy
    Liu, Yu
    Tang, Haocheng
    Song, Tianchi
    Xu, Mengxin
    Chen, Junyi
    Cui, Xi-Yang
    Han, Yuxiang
    Li, Zhu
    Liu, Zhibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (09) : 2636 - 2646
  • [2] Organotrifluoroborate Enhances Tumor Targeting of Fibroblast Activation Protein Inhibitors for Targeted Radionuclide Therapy
    Liu, Y.
    Xu, M.
    Chen, J.
    Cui, X.
    Liu, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S763 - S764
  • [3] Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy
    Yu Liu
    Haocheng Tang
    Tianchi Song
    Mengxin Xu
    Junyi Chen
    Xi-Yang Cui
    Yuxiang Han
    Zhu Li
    Zhibo Liu
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2636 - 2646
  • [4] Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model
    Ceuppens, Hannelore
    Antunes, Ana Rita Pombo
    Navarro, Laurent
    Ertveldt, Thomas
    Berdal, Marion
    Nagachinta, Surasa
    De Ridder, Kirsten
    Lahoutte, Tony
    Keyaerts, Marleen
    Devoogdt, Nick
    Goyvaerts, Cleo
    D'Huyvetter, Matthias
    Breckpot, Karine
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025, 52 (02) : 444 - 457
  • [5] Efficient α and β-Radionuclide Therapy Targeting Fibroblast Activation Protein-α in a Fast-Growing Preclinical Tumour Model
    Ceuppens, H.
    Antunes, A. Pombo
    Navarro, L.
    Ertveldt, T.
    Berdal, M.
    Nagachinta, S.
    De Ridder, K.
    Keyaerts, M.
    Devoogdt, N.
    Goyvaerts, C.
    D'Huyvetter, M.
    Breckpot, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S386 - S386
  • [6] Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?
    Rubel Chakravarty
    Wenyu Song
    Sudipta Chakraborty
    Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2935 - 2939
  • [7] Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?
    Chakravarty, Rubel
    Song, Wenyu
    Chakraborty, Sudipta
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (10) : 2935 - 2939
  • [8] Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
    Muhsin H. Younis
    Sara Malih
    Xiaoli Lan
    Mohammad Javad Rasaee
    Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 1773 - 1777
  • [9] Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
    Younis, Muhsin H.
    Malih, Sara
    Lan, Xiaoli
    Rasaee, Mohammad Javad
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (06) : 1773 - 1777
  • [10] Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
    Dirk Zboralski
    Aileen Hoehne
    Anne Bredenbeck
    Anne Schumann
    Minh Nguyen
    Eberhard Schneider
    Jan Ungewiss
    Matthias Paschke
    Christian Haase
    Jan L. von Hacht
    Tanya Kwan
    Kevin K. Lin
    Jan Lenore
    Thomas C. Harding
    Jim Xiao
    Andrew D. Simmons
    Ajay-Mohan Mohan
    Nicola Beindorff
    Ulrich Reineke
    Christiane Smerling
    Frank Osterkamp
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3651 - 3667
12345